See more : GANESH HOLDINGS LTD. (GANHOLD.BO) Income Statement Analysis – Financial Results
Complete financial analysis of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (YIHCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of YiChang HEC ChangJiang Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- MariMed Inc. (MRMD) Income Statement Analysis – Financial Results
- Paramount Group, Inc. (PGRE) Income Statement Analysis – Financial Results
- Shanghai Guijiu Co.,Ltd. (600696.SS) Income Statement Analysis – Financial Results
- PZ Cormay S.A. (CRM.WA) Income Statement Analysis – Financial Results
- Hill International, Inc. (HIL) Income Statement Analysis – Financial Results
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (YIHCF)
About YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases, and cardiovascular diseases in the People's Republic of China. It also manufactures and sells active pharmaceutical ingredients; researches and develops medical devices and drugs, as well as biotechnology; and provides medical consulting services. The company sells its products to hospitals and medical institutions through a network of distributors. It has a strategic cooperation framework agreement with Alibaba Health Technology (China) Limited to carry out influenza special projects; Jointown Pharmaceutical Group Co., Ltd.; Guangdong Yihao Pharmaceutical Co., Ltd.; and Shenzhen HEC Industrial Development Co., Ltd, as well as strategic cooperative partnership with China National Accord Medicines Corporation Ltd. The company was formerly known as Yichang Changjiang Pharmaceutical Company Limited and changed its name to YiChang HEC ChangJiang Pharmaceutical Co., Ltd. in May 2015. The company was incorporated in 2001 and is based in Yichang, China. YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a subsidiary of Guangdong HEC Technology Holding Co., Ltd.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 6.29B | 3.74B | 913.79M | 2.35B | 6.22B | 2.51B | 1.60B | 941.50M | 692.91M | 440.90M |
Cost of Revenue | 1.31B | 898.88M | 430.09M | 351.55M | 921.82M | 398.81M | 280.42M | 214.23M | 178.33M | 119.83M |
Gross Profit | 4.99B | 2.85B | 483.70M | 2.00B | 5.30B | 2.11B | 1.32B | 727.27M | 514.58M | 321.08M |
Gross Profit Ratio | 79.21% | 76.00% | 52.93% | 85.03% | 85.19% | 84.11% | 82.49% | 77.25% | 74.26% | 72.82% |
Research & Development | 192.29M | 129.61M | 109.67M | 92.45M | 162.62M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 385.70M | 338.45M | 358.40M | 410.52M | 508.15M | 384.39M | 192.99M | 132.71M | 120.17M | 110.31M |
Selling & Marketing | 1.55B | 1.22B | 521.67M | 1.15B | 2.36B | 653.65M | 372.09M | 180.89M | 77.29M | 60.12M |
SG&A | 1.94B | 1.56B | 880.07M | 1.56B | 2.87B | 1.04B | 565.08M | 313.60M | 197.46M | 170.43M |
Other Expenses | 499.80M | 172.00K | 60.00K | 255.20M | -4.61M | 5.51M | -337.00K | -2.00M | -1.33M | -27.00K |
Operating Expenses | 2.63B | 1.67B | 924.53M | 1.55B | 2.86B | 1.03B | 557.99M | 305.70M | 183.83M | 136.90M |
Cost & Expenses | 3.94B | 2.57B | 1.35B | 1.91B | 3.78B | 1.43B | 838.41M | 519.94M | 362.16M | 256.73M |
Interest Income | 57.78M | 6.74M | 11.35M | 24.99M | 36.04M | 14.60M | 14.74M | 8.10M | 2.17M | 21.30M |
Interest Expense | 227.40M | 281.65M | 243.81M | 244.21M | 204.50M | 1.42M | 4.29M | 7.23M | 24.90M | 42.33M |
Depreciation & Amortization | 391.27M | 377.36M | 259.82M | 122.73M | 86.19M | 61.09M | 43.80M | 27.45M | 25.75M | 31.95M |
EBITDA | 2.75B | 698.43M | -163.56M | 1.38B | 2.56B | 1.16B | 796.28M | 487.75M | 365.35M | 237.39M |
EBITDA Ratio | 43.62% | 33.25% | -13.18% | 43.42% | 41.13% | 46.40% | 49.74% | 51.82% | 52.73% | 53.84% |
Operating Income | 2.35B | 321.07M | -423.38M | 1.25B | 2.47B | 1.10B | 752.48M | 460.30M | 339.61M | 205.45M |
Operating Income Ratio | 37.40% | 8.57% | -46.33% | 53.43% | 39.74% | 43.97% | 46.98% | 48.89% | 49.01% | 46.60% |
Total Other Income/Expenses | -227.43M | -281.65M | -243.81M | -244.21M | -204.50M | -1.42M | -4.29M | -7.23M | -24.90M | -42.33M |
Income Before Tax | 2.13B | 39.42M | -667.18M | 1.01B | 2.27B | 1.10B | 748.20M | 453.07M | 314.71M | 163.12M |
Income Before Tax Ratio | 33.79% | 1.05% | -73.01% | 43.03% | 36.46% | 43.91% | 46.72% | 48.12% | 45.42% | 37.00% |
Income Tax Expense | 270.95M | -9.82M | -79.46M | 173.02M | 361.87M | 201.11M | 121.84M | 72.47M | 48.96M | 27.77M |
Net Income | 1.99B | 76.60M | -587.65M | 839.46M | 1.92B | 942.54M | 647.10M | 380.60M | 265.75M | 135.34M |
Net Income Ratio | 31.66% | 2.05% | -64.31% | 35.75% | 30.83% | 37.54% | 40.40% | 40.42% | 38.35% | 30.70% |
EPS | 2.26 | 0.09 | -0.67 | 0.95 | 2.16 | 1.04 | 0.72 | 0.42 | 0.40 | 0.15 |
EPS Diluted | 2.26 | 0.09 | -0.67 | 0.53 | 2.07 | 1.04 | 0.72 | 0.42 | 0.40 | 0.15 |
Weighted Avg Shares Out | 879.97M | 879.97M | 879.97M | 1.11B | 1.01B | 904.05M | 903.81M | 901.63M | 671.13M | 901.32M |
Weighted Avg Shares Out (Dil) | 879.97M | 879.97M | 879.97M | 1.11B | 1.01B | 904.05M | 903.81M | 901.63M | 671.13M | 901.32M |
Source: https://incomestatements.info
Category: Stock Reports